Lipidil (fenofibrate) is now indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy.1 This indication is based on two large randomised controlled trials; the FIELD and ACCORD clinical trials.2,3
Within 20 years of their diagnosis the majority of patients with type 2 diabetes will develop diabetic retinopathy – a progressive disease that can cause blindness if left untreated.4,5 Lipidil does not replace control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.1
Lipidil is also indicated as an adjunct to diet in the treatment of hypercholesterolaemia; types II, III, IV and V dyslipidaemia; and dyslipidaemia associated with type 2 diabetes.1
Contact your Abbott representative.
1. Lipidil Approved Product Information
2. Keech AC, et al. Lancet. 2007; 370: 1687–1697.
3. ACCORD Study Group. N Engl J Med. 2010; 363: 233-244.
4. Yau JWY, et al. Diabetes Care. 2012; 35: 556–564.
5. Fong DS, et al. Diabetes Care. 2003; 26: 1 s99-s102.
Product Information available from www.medicines.org.au/files/abplipid.pdf